EZH2 mutations increase the heterogeneity of chromatin states in lymphoma

TL;DR

EZH2 mutations in B-cell lymphoma change chromatin states and increase cell diversity.

Contribution

The study shows EZH2 mutations reprogram chromatin and increase heterogeneity in lymphoma cells.

Findings

EZH2 gain-of-function mutations reprogram chromatin states in B-cell lymphoma.

These mutations increase cell-cell heterogeneity in lymphoma.

Single-cell histone modification measurements revealed these effects.

Abstract

A recent study in PLoS Biology used simultaneous measurements of histone modifications in single cells to reveal that EZH2 gain-of-function mutations profoundly reprogram chromatin states in B-cell lymphoma, while also increasing their cell–cell heterogeneity.

This Primer discusses a recent study using simultaneous measurements of histone modifications in single cells to reveal that EZH2 gain-of-function mutations profoundly reprogram chromatin states in B-cell lymphoma, while also increasing their cell-cell heterogeneity.

Figures

A](#pbio.3003211.g001)). This approach allowed the authors to examine the detailed impact of recurrent *KMT2D* and *EZH2* mutations on the histone modification landscape and its cell-cell variability, both in patient-derived xenografts and isogenic DLBCL cell lines.

Full text

The transcription programs that underpin differentiation and cell identity depend on the concerted action of transcription factors and chromatin modifiers. Oncogenesis involves a weakening of cell identity and, as such, is very frequently associated with alterations in chromatin regulators [1].

This is especially striking in germinal-center-B cell-like diffuse large B cell lymphomas (GCB-DLBCL) and follicular lymphomas (FL), which both feature mutations in key histone-modifying enzymes in more than half of patients [2,3]. These lymphomas arise within germinal centers (GCs), where activated B cells normally undergo affinity maturation as they prepare to differentiate into plasma cells and memory B cells. The GC reaction involves cycles of somatic hypermutation and clonal expansion, processes that create inherent vulnerability to malignant transformation [2,3].

Normal GC formation and function require transient upregulation of EZH2, a conserved histone H3 lysine 27 (H3K27) methyltransferase. In GC B cells, EZH2 targets key regulators of proliferation checkpoints and differentiation programs whose temporary suppression is critical for successful affinity maturation [4,5]. Subsequent failure to reduce EZH2 activity, however, could drive cells toward lymphomagenesis. Indeed, approximately 1 in 4 FL and GCB-DLBCL tumors present heterozygous gain-of-function (GOF) mutations in EZH2, resulting in elevated H3K27 trimethylation (H3K27me3) [6,7]. This excess EZH2 activity has been linked to aberrant repression of genes required for differentiation accompanied by GC hyperplasia and transformation [4], although the underlying mechanism remains incompletely understood.

Another histone modifier recurrently mutated in GC-derived lymphomas is KMT2D, which monomethylates H3K4 [2,3]. In mouse models, such loss-of-function KMT2D mutations obstruct differentiation and increase proliferation of GC B cells, thus promoting the emergence of lymphomas [8,9]. Intriguingly, mutations in KMT2D and EZH2, as well as loss-of-function mutations in the gene encoding the histone acetyltransferase CREBBP, are often found in combination in FL and GCB-DLBCL, indicating that they confer partly non-overlapping advantages to tumor cells.

While several studies have investigated the contributions of individual histone modifier alterations to lymphomagenesis, how these different mutations interact when they co-occur is not well understood. The extent to which disruption of these enzymes perturbs the chromatin landscape more generally, through the complex network of crosstalk with other pivotal histone modifications, is also unclear. Finally, whether these mutations are uniform or variable in their impact on histone modification profiles and gene expression programs across different cells is an underexplored question with important clinical implications. Indeed, intercellular heterogeneity plays a key role in tumor adaptation and evolution, and achieving a precise understanding of a tumor’s constituent cellular phenotypes has the potential to dramatically improve the efficacy of therapeutic interventions.

In a new study in PLoS Biology, Griess and colleagues sought to address all these aspects of histone modifier function in lymphomagenesis. To do so, they applied a single-cell methodology, Cytometry by Time of Flight (CyTOF), to quantify the levels of 16 different histone modifications and several other markers simultaneously in large numbers of GCB-DLBCL cells [10]. Then, using dimensionality reduction and other analyses, they extracted patterns of co-variation among histone modifications and classified individual cells into clusters based on their overall profiles of histone mark abundance (Fig 1A). This approach allowed the authors to examine the detailed impact of recurrent KMT2D and EZH2 mutations on the histone modification landscape and its cell-cell variability, both in patient-derived xenografts and isogenic DLBCL cell lines.

The data reveal that impaired KMT2D and enhanced EZH2 activity have quite distinct effects on the lymphoma epigenome. The impact of a KMT2D null mutation is relatively mild, with little change in H3K4me1 itself and instead modest increases in H3K36me2 and H4K16ac. By contrast, an EZH2 GOF mutation causes a substantial shift toward H3K27me3 at the expense of H3K27me2, as expected, but also a sharp loss of H3K9me2. Strikingly, combining these mutations produces the same CyTOF profile as EZH2 GOF alone, indicating that EZH2 mutations are epistatic to KMT2D loss in DLBCL. Further supporting this notion, the authors observe expression changes in a small number of genes in KMT2D-null cells, but these are not recapitulated in EZH2-GOF/KMT2D double-mutant cells. Instead, the double-mutant transcriptome matches the extensive alterations seen in EZH2-GOF single-mutant cells. Thus, the EZH2 GOF mutation induces comparatively drastic changes and exhibits epistasis over KMT2D loss of function.

In addition to these properties, the authors’ powerful single-cell approach enabled them to uncover another distinctive feature of EZH2 GOF DLBCL cells, which is their markedly increased cell-cell heterogeneity in histone modification profiles compared to KMT2D-mutant or unmodified counterparts. This is evident both from defined metrics and from their segregation into distinct clusters in dimensionality reduction plots. A clear majority of cells form a population with strong attributes of the EZH2-mutant epigenomic profile, termed “extreme” by the authors, while a smaller “WT-like” group clusters with EZH2-WT cells (Fig 1B).

Remarkably, the authors could show through subcloning experiments that this bimodal behavior reappears in virtually every clonal population, suggesting that cells are able to shift dynamically between these distinct states. Given that the “WT-like” cells are not as sensitive to EZH2 inhibition as the “extreme” subpopulation, this transition capability raises important implications for targeted therapy. Indeed, EZH2-mutant tumors show encouraging but incomplete responses to EZH2 inhibitors in the clinic. The authors’ findings suggest that this limitation might be attributable to “WT-like” cells, for which complementary treatment strategies will need to be devised.

Beyond these novel insights into the impact of EZH2 and KMT2D mutations at the single-cell level in DLBCL, the authors also demonstrated the more general statistical power of these types of datasets by developing new computational analysis pipelines. Thoroughly exploiting their simultaneous measurements of abundance of many histone modifications in many individual cells, they extracted a network model that infers the directionality of causal relationships between changes in different modifications. The complexity of the crosstalk between histone modifications can make such links otherwise difficult to discern, therefore making these new approaches uniquely valuable.

An important goal for future studies will be to determine the locally acting mechanisms that underlie these relationships in global levels of histone marks, especially in the context of lymphomas carrying mutations in histone modifiers. Which molecular encounters along the chromatin can explain the profound shifts and increased heterogeneity revealed in this work? The epistasis relationship uncovered here also raises questions regarding the advantage for lymphomas of simultaneous KMT2D and EZH2 mutations, which future investigations will help clarify. This study’s findings open several new research directions that promise to yield even more advances in the years ahead.